Advanced search
Publication Cover
Emerging Drugs Volume 6, 2001 - Issue 1
Journal homepage
36
Views
2
CrossRef citations to date
0
Altmetric
Review

Serotonergic modulation and irritable bowel syndrome

Richard Borman Pharmagene plc, 2 Orchard Road, Royston, Herts., SG8 5HD, UK. [email protected]
Pages 57-68 | Published online: 24 Feb 2005

Bibliography

  • Kirsner JB (Ed.), Lea & Febiger, Philadelphia, USA (1993):419–432.
  • DROSSMAN DA, RICHTER JE, TALLEY NJ, et al: Thefunctional gastrointestinal disorders: diagnosis, pathophysiology and treatment. McLean VA (Ed.), Degnon Associates (1994).
  • DROSSMAN DA, CORAZZIARI E, TALLEY NJ, et al.: Rome II.The functional gastrointestinal disorders. Diagnosis, pathophysiology and treatment: a multinational consensus. McLean VA (Ed.), Degnon Associates (2000).
  • •Complete description of criteria for diagnosis of IBS.
  • DROSSMAN DA, CORAZZIARI E, TALLEY NJ, et al: Rome II: A multinational consensus document on functional gastrointestinal disorders. Gut (1999) 45 (II):111–1181.
  • •Complete description of criteria for diagnosis of IBS.
  • BEARCROFT CP, PERRETT D, FARTHING MJ: Postpran- dial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut (1998) 42(1):42–46.
  • ••Evidence for the possible involvement of 5-HT in IBS.
  • READ NW, GWEE K-A: The importance of
  • -hydroxytryptamine receptors in the gut. Pharmacol. Ther. (1994) 62:159–173.
  • ••Excellent review article on 5-HT receptor subtypes in the GItract of a number of species, including humans.
  • HOYER D, CLARKE DE, FOZARD JR, HARTIG PR, et al: International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmac. Rev. (1994) 46:157–203.
  • THOMPSON WG: Irritable bowel syndrome:prevalence, prognosis and consequences. Can. Med. Assoc. J. (1986) 1 3 4 (2):111–113.
  • DROSSMAN DA, LIZ, ANDRUZZI E, et al.: US householdersurvey of functional gastrointestinal disorders: prevalence, sociodemography and health impact. Dig. Dis. Sci. (1993) 38:1569–1580.
  • HEATON KW, O'DONNELL LJD, BRADDON FEM, et al: Symptoms of irritable bowel syndrome in a British urban community: consulters and nonconsulters. Gastroenterology (1992) 1 02 :1962–1967.
  • THOMPSON WG, HEATON KW, SMYTHE GT, SMYTHE C:Irritable bowel syndrome in general practice. Gastro-enterology (1997) 112:A837.
  • Thompson WG (Ed.), Plenum, New York, USA (1989):181–211.
  • Current Topics in Gastroenterology and Hepatology.Thompson WG, Tytgat GNJ, Van Blankenstein M (Eds.), Springer-Verlag, New York, USA (1990236–245.
  • CANN PA, READ NW, HOLDSWORTH CD, BARENDS D: Role of loperamide and placebo in management of irritable bowel syndrome. Dig. Dis. sa. (1984) 29:239–247.
  • AWOUTERS F, MEGENS A, VERLINDEN M, et al: Lopera-mide: survey of studies on mechanism of its activity. Dis. ScL (1993) 38:977–995.
  • EHERER AJ, SANTA ANA CA, PORTER J, FORTRAN JS: Effect of psyllium, calcium polycarbophil and wheat bran on secretory diarrhoea induced by phenolphthein. Gastroenterology (1993) 104:1007–1012.
  • WRIGHT SH, SNAPE WJ, BATTLE W, COHEN S, LONDON RL: Effect of dietary components on gastrocolonic response. Am. J. Physiol (1980) 2 3 8:G228–G232.
  • FEINMANN C: Pain relief by antidepressants. Pain (1985) 23:1–8.
  • CLOUSE RE: Antidepressants for functional gastroin-testinal symptoms. Dig. Dis. sa. (1994) 39:2352–2363.
  • O'MALLEY PG, JACKSON JL, SANTORO J, et al: Antide-pressant therapy for unexplained symptoms and symptom syndromes. J. Pam. Pract. (1999) 48 (12):980–990.
  • BAKER DE: New drugs approved by the FDA; new dosage forms and indications; agents pending FDA approval; major labelling changes. Hosp. Pharm. (2000) 35(5):536–548.
  • CAMILLERI M, MAYER EA, DROSSMAN DA, et al: Improve-ment in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment. Pharmacol. Ther. (1 9 9 9) 13 (9):1149–1159
  • BEGLINGER C, HILDEBRAND P, BUEREN TV, et al.: Effectof cilansetron, a specific 5-HT-3 receptor antagonist, on gastrointestinal motor function in normal subjects. Naunyn Schmiedeberg's Arch. Pharmacol. (1996) 353 (4):R163.
  • WHORWELL PJ, KRUMHOLZ S, MULLER-LISSNER S, et al: Tegaserod has a favorable safety & tolerability profile in patients with constipation predominant and alternating forms of irritable bowel syndrome. Gastro-enterology (2000) 11 8 (4) :A5529.
  • JOHANSEN JF, MINER PB, PARKMAN HB, et al: Prucalo-pride (PRU) significantly improves symptoms (SX) associated with chronic constipation (CC). Gastroenter-ology (2000) 11 8 (4):A5027.
  • SCHNEIDER HR, OTTEN M, WURZER H, et al.: Long-term treatment with prucalopride is safe and well tolerated in patients with chronic constipation. Gastroenterology (2000) 118 (4):A5493.
  • MARQUIS P, JOHANSEN JF, MINER PB, et al.: Prucalopride (PRU) significantly improves patient (PT) quality of life (QOL) and satisfaction level in chronic constipa-tion (CC). Gastroenterology (2000) 118 (4):A5044.
  • TALLEY NJ: 5-Hydroxytryptamine agonists and antago- nists in the modulation of gastrointestinal motility and sensation: clinical implications. Aliment. Pharmacol. Ther. (1992) 6:273–289.
  • •Early review article on the putative role of 5-HT receptor modulation in the treatment of GI disorders.
  • BRIEJER MR, SCHUURKES JA: 5 -HT3 and 5receptors and cholinergic and tachykinergic neurotransmission in the guinea-pig proximal colon. Eur. J. Pharmacol (1996) 308:173–180.
  • JIN JG, FOXX-ORENSTEIN AE, GRIDER JR: Propulsion in guinea pig colon induced by 5-hydroxytryptamine OM via 5-HT4 and 5-HT3 receptors. J. Pharmacol Exp. Ther. (1999) 288:93–97.
  • GRAF S, SARNA SK: 5-HT-induced colonic contractions: enteric locus of action and receptor sub-types. Am. J Physiol (1997) 273:G68–G74.
  • GOLDBERG PA, KAMM MA, SETTI-CARRARO P, VAN DER SIJP, JR., ROTH C: Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antago-nism (ondansetron). Digestion (1996) 7 (6):478–483.
  • BORMAN RA, BURLEIGH DE: Functional evidence for a 5-HT2B receptor mediating contraction of longitudinal muscle in human small intestine. Br. J. Pharmacol (1995) 114:1525–1527.
  • BORMAN RA, BURLEIGH DE: 5-HT1D and 5-HT2B receptors mediate contraction of smooth muscle in human small intestine. Ann. NY Acad. Sci. (1997) 812:327–328.
  • BORMAN RA, BURLEIGH DE: Evidence for the involve- ment of a 5-HT4 receptor in the secretory response of human small intestine to 5-HT. Br. J. Pharmacol (1993) 110:927–928.
  • •Evidence that 5-HT4 receptor modulation may affect ion and fluid transport in human intestine.
  • BORMAN RA, BURLEIGH DE: Heterogeneity of 5-HT receptors in human sigrnoid colon. Br. J. Pharmacol. (1994) 112:558P.
  • TAM FS, HILLIER K, BUNCE KT: Characterization of the 5-hydroxytryptamine receptor type involved in inhibition of spontaneous activity of human isolated colonic circular muscle. Br. J Pharmacol. (1994) 113(0:143–150.
  • HILLIER K, TAM FS-F, BUNCE KT, GROSSMAN C: Inhibi-tion of motility induced by the activation of 5-HT1-like and 5-HT4-like receptors in isolated human colon smooth muscle. Br. J. Pharmacol (1994) 112:102P.
  • BORMAN RA, BURLEIGH DE: Human colonic mucosa possessesamixedpopulationof5-hydroxytryptamine receptors. Eur. J. Pharmacol. (1996) 309:271–274.
  • PRINS NH, BRIEJER MR, VAN BERGEN PJ, AKKERMANS LM, SCHUURKES JA: Evidence for 5-HT7 receptors mediating relaxation of human colonic circular smooth muscle. Br. J. Pharmacol. (1999) 128(4):849–852.
  • MISIEWICZ JJ, WALLER SL, EISNER, M: Motor responses of human gastrointestinal tract to 5-hydroxytryptamine in vivo and in vitro. Gut (1966) 7:208–216.
  • COSTALL B, NAYLOR RJ: 5-hydroxytryptamine: new receptors and novel drugs for gastrointestinal motor disorders. Scand.J. Gastroenterol. (1990) 25:769–787.

Websites

  • www.ibsgroup.org Irritable Bowel Syndrome Self Help Group.
  • www.medinfo.co.uk/conditions/ibs.html Medinfo: Irritable Bowel Syndrome.
  • www.aboutibs.org/characteristics.html International Foundation for Functional Gastrointestinal Disorders: Characteristics of IBS.
  • www.ibsandhealth.com/public/health/01/symptoms/ 01 html ibsandhealth.com (Novartis): Signs and Symptoms of IBS.
  • www.iddb3.com Current Drugs Ltd.: Investigational Drugs database.
  • ••An excellent source of information regarding upcomingtreatments and research strategies in the treatment of IBS.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.